Chargement en cours...
Gefitinib suppresses cervical cancer progression by inhibiting cell cycle progression and epithelial-mesenchymal transition
Cervical cancer (CC) is the second most common malignant cancer among women. Gefitinib was one of the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in clinical trials. However, the underlying mechanism of gefitinib in regulating CC progression remains unknown. In the c...
Enregistré dans:
| Publié dans: | Exp Ther Med |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
D.A. Spandidos
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6676113/ https://ncbi.nlm.nih.gov/pubmed/31410143 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2019.7754 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|